Nathalie Francillard

Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.

M. Griesshammer, S. Verstovsek, M. Hino, 2020, The Lancet. Haematology.

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

M. Cazzola, M. Griesshammer, S. Verstovsek, 2016, Haematologica.

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis

D. Niederwieser, A. Vannucchi, C. Harrison, 2018, Haematologica.

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

M. Griesshammer, S. Verstovsek, M. Hino, 2018, Blood.

Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)

M. Griesshammer, S. Verstovsek, M. Hino, 2017 .

Ruxolitinib in polycythemia vera: Follow-up from the RESPONSE trial.

M. Griesshammer, S. Verstovsek, M. Hino, 2015 .